Amgen (AMGN) Price Target Raised to $138 at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/11/2024
- Xponential Fitness (XPOF) removes Anthony Geisler from his duties and suspended him indefinitely as CEO
- NVIDIA (NVDA) PT Raised to $1,350 at HSBC, 'NVL36/NVL72 server rack pricing power major driver in 2025'
- Shift4 Payments (FOUR) PT Lowered to $100 at Evercore ISI, '#4 Top Pick'
- Kinetik Holdings (KNTK) to Acquire Durango
- United Bankshares (UBSI) to Acquire Piedmont Bancorp, Inc.
- Midday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall
- After-hours movers: Akamai Technologies, Unity, Macrogenics and more
- Midday movers: Roblox, Airbnb fall; Trade Desk, AppLovin and Bumble rise
- After-hours movers: Robinhood, AppLovin rise; Airbnb, Arm fall, and more
- Midday movers: Uber, Rivian, Twilio fall; Reddit and Arista rise
Amgen (AMGN) Deal for Onyx a Positive on Oncology Expansion & EPS Accretion - Jefferies
August 26, 2013 7:54 AM EDTJefferies analyst Eun K. Yang, Ph.D. boosted his price target on Amgen (NASDAQ: AMGN) from $123 to $130 following the deal to acquire Onyx Pharmaceuticals (NASDAQ: ONXX).
"We view the deal as positive (oncology franchise expansion) and... More
Amgen's (AMGN) / Onyx (ONXX) Deal Viewed as Strategic Positive
August 26, 2013 7:47 AM EDTOn Sunday, Amgen (NASDAQ: AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) agreed on a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. In the view of Goldman... More
Piper Jaffray Upgrades Amgen (AMGN) to Overweight
August 26, 2013 6:42 AM EDTPiper Jaffray upgraded Amgen (NASDAQ: AMGN) from Neutral to Overweight with a price target of $140.00 (from $120.00).
For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.
Shares of Amgen closed at $105.60 yesterday, with a 52 week range of $80.60-$114.95.... More
Amgen (AMGN) to Acquire Onyx Pharma (ONXX) for $125/Share
August 25, 2013 10:24 PM EDTOn Sunday, Amgen (NASDAQ: AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) agreed on a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash. The deal comes at a premium to the $120 per share bid Amgen announced in July, that was rebuffed by Onyx, and Friday's closing price for Onyx of $116.96.
Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of... More
UPDATE: Amgen (AMGN) to Push for Lower Price on Onyx (ONXX) - Bloomberg
August 22, 2013 2:44 PM EDT(Updated - August 22, 2013 2:53 PM EDT)
Amgen (Nasdaq: AMGN) plans to push for lower price on Onyx (Nasdaq: ONXX), according to Bloomberg. Sources said Onyx would not provide Amgen additional data on blood... More
Onyx (ONXX) Higher After Opening Up Kyprolis Data to Amgen (AMGN) & Others
August 22, 2013 7:50 AM EDTOnyx Pharmaceuticals, Inc. (Nasdaq: ONXX) stock moved higher early on Thursday after the company gave potential buyers access to data on its new blood cancer drug, Kyprolis. The company is in talks with Amgen (Nasdaq: AMGN) and... More
